MET and neoplasm: Most notably, cabozantinib, a pan-tyrosine kinase inhibitor with high affinity for c-MET and VEGFR2, is being tested in a phase II clinical trial for recurrent GBM with encouraging tumor responses and acceptable toxicity (Zhang et al., 2010).